retatrutide glp-1 medication Weight Loss Results:Trial Data and FDA Status Retatrutide vs Tirzepatide Compared |

The nuanced version of the verdict: For pure fat loss efficacy: Retatrutide leads clearly

Investigated in rodent and non-human primate models of diet-induced obesity, hepatic steatosis and glycaemic dysregulation

Minimizing concentration-dependent adverse events: Evaluate whether dose-splitting might reduce peak-related gastrointestinal symptoms based on pharmacokinetic modeling

Affordability meets safety

Some research investigates transdermal delivery of small-molecule GLP-1 receptor agonists or modified peptides, but these remain in early development stages

When comparing the two, tirzepatide had slightly lower dropout rates due to GI symptoms (about 3%) compared to semaglutide (about 6%)